Our Team

Jordan Lane Ignota Labs co-CEO CSO scientific lead proactive in silico safety screening toxicity

Jordan Lane

CSO - Chief Scientific Officer

Jordan is the Chief Scientific Officer at Ignota Labs. With a BSc in Biochemistry and Genetics, as well as a PhD in Alzheimer's Biomarkers and Biophysics from Nottingham University, he has dedicated his career to the forefront of drug discovery. Jordan's vast experience encompasses contract research organisations, big pharma, and biotech firms, with his work ranging from cellular synergy assays to high-throughput screening of 1.8 mn compounds. He has led multiple drug discovery programs, two which are in Phase II clinical trials. In addition to his scientific accomplishments, Jordan completed an MBA from Quantic in 2022.

Sam Windsor Ignota Labs co-CEO commercial lead  COO CFO proactive in silico safety screening toxicity

Sam Windsor

CEO - Chief Executive Officer

Sam is the Chief Executive Officer of Ignota Labs. Sam is a former mathematician, recovering management consultant and leader in utilising AI/data-driven solutions to solve healthcare-related problems. He has an MBA from INSEAD Business School, a Masters in Mathematics from Nottingham University and wide-ranging experience across the healthcare ecosystem, including NHS, HealthTech companies, Big Pharma, pharmacy chains and hospital trusts. He has worked with a range of organisations, from startups to large companies and public sector organisations.

Layla Hosseini Gerami Ignota Labs CDSO machine learning ai proactive in silico safety screening toxicity

Layla Hosseini-Gerami

CDSO - Chief Data Science Officer

Layla is the Chief Data Science Officer at Ignota Labs and leads the development of our cutting-edge AI solutions. Her PhD in Molecular Informatics from the University of Cambridge focused on using machine learning and network biology methods for drug mechanisms of action. Her research has been applied at Eli Lilly, Addenbrooke's Hospital, and the US Environmental Protection Agency. She was Co-Chief Operating Officer at Downing Enterprise, an innovation competition providing funding for student-led startups. Layla holds an MChem and BSc in Chemistry from the University of Leeds.

Sarthak Grover

Business Strategist

Sarthak works on business strategy at Ignota Labs. Sarthak holds a B.A. in Economics and Political Science from Union College, NY, and an MBA from INSEAD. His experience spans Economics consulting at the Economist Intelligence Unit to sales and strategy leadership at early-stage tech startups. He is passionate about healthcare, having worked on the world’s largest global assessment of health security capabilities with the Johns Hopkins Centre for Health Security, and with public health leaders including WHO to build digital health tools.

Sara Masarone

Machine Learning Researcher

Sara is a Machine Learning Researcher at Ignota Labs. She holds a PhD from The Alan Turing Institute and Queen Mary University of London in Multi-Omics data integration using Graph Neural Networks. Sara's research and experience revolve around integrating biological data to gain insights into various biological processes and building models for prognosis and diagnosis. Before joining Ignota Labs she also worked on Variational Autoencoders at Inflammatix and worked on projects that resulted in a publication at a NeurIPS workshop.

Matt Wilkinson, Machine Learning Engineer, In silico toxicity predictions, drug discovery, machine learning, ai

Matt Wilkinson

Machine Learning Engineer

Matt is a Machine Learning Engineer at Ignota Labs. He holds a PhD in Artificial Intelligence and Cheminformatics from the University of Bath. Matt also has an MChem in Chemistry for Drug Discovery. Matt’s research and career interests involve applying AI, specifically deep learning, to create impactful solutions to real-world challenges. Beyond chemical AI applications, Matt was part of The Alan Turing Institute’s internship network, where he developed a novel neural architecture for spacio-temporal forecasting and anomaly detection in road traffic systems.

Advisors

Andreas Bender

Professor University of Cambridge
Healx, PharmEnable Co-Founder

Anne Phelan

CSO, BenevolentAI

Carolin Schramm

Nonclinical Safety Expert, Sanofi

Matt Segall

CEO, Optibrium

Jan Lessem

Experienced Clinical Research and Drug Development Consultant

Simon Chell

VP Drug Discovery, AstraZeneca